Symbio Pharmaceuticals Limited (JP:4582)
:4582
Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥81.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥5.77B
Enterprise Value¥3.97B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.66
Shares Outstanding59,567,080
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Focus & In-licensing ModelSymbio’s business model concentrates on specialty oncology and hematology and relies on in-licensing and partner commercialization. This model lowers fixed capital intensity, leverages external R&D and distribution capabilities, and can deliver durable, scalable revenue streams once approvals and partnerships convert into launched products.
High Product-level Gross MarginsPersistently strong gross margins indicate attractive product-level economics and pricing power for approved specialty medicines. If Symbio controls operating and SG&A costs or achieves greater scale, these high gross margins provide a structural pathway to restoring operating profitability over the medium term.
Meaningful Asset BaseA meaningful asset base supports ongoing R&D, regulatory activities and gives the company collateral for financing or partner transactions. This durable resource provides optionality to fund development through asset sales, licensing, or secured financing, helping bridge periods of operating cash shortfall.
Bears Say
Multi-year Revenue DeclineSustained revenue contraction erodes scale economics and reduces operating leverage, making it harder to cover fixed R&D and commercial costs. Over a multi-quarter horizon, falling top-line trends weaken bargaining power with partners, increase per-unit costs, and heighten execution risk for pipeline commercialization.
Heavy Cash Burn And Negative Cash FlowMaterial negative operating and free cash flow signal the company is not self-funding its operations or development. This persistent cash burn creates reliance on external financing, raises dilution or refinancing risk, and constrains the company’s ability to invest in trials or commercialization without partner support.
New Leverage And Equity ErosionThe introduction of meaningful debt after years of zero leverage reduces financial flexibility and increases interest and covenant risk. With a compressed equity base from sustained losses, higher leverage limits ability to raise inexpensive capital and increases the chance of adverse financing terms if losses continue.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥81.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.77B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is May 07, 2026 which is in 16 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported -¥21.66 earnings per share for the quarter, missing the consensus estimate of N/A by -¥21.66.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 59,567,080 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥21.66 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―